Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | IARS1 | P41252 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20306056 | 0.82 | MEN1 (0.48) | MEN1KMT2ARECQL | |
| SCHEMBL12385783 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL85848 | 0.79 | CYP2D6 (0.43) | MEN1KMT2A | |
| SCHEMBL14493157 | 0.79 | KMT2A (0.48) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL12523122 | 0.79 | MAPK1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL24851402 | 0.79 | MEN1 (0.43) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL16316315 | 0.79 | MEN1 (0.54) | MEN1KMT2ARECQL | |
| SCHEMBL13848563 | 0.79 | MEN1 (0.54) | MEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL22742401 | 0.78 | EPHX1 (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL22844702 | 0.78 | MCL1 (0.55) | MEN1KMT2AALDH1A1IARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LTD (IN) | 2022-02-17 | — | — | US | disclosed |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | CELLIX BIO PRIVATE LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IL1B, IL36G, IL17A | MEN1 4256/4885KMT2A 4393/4885RECQL 1889/4885 |
| US-20220162156-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | MEN1 3871/4885KMT2A 4756/4885RECQL 245/4885 |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | MEN1 999/4885KMT2A 4424/4885RECQL 625/4885 |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | SI, HBG2, HBG1 | MEN1 999/4885KMT2A 4424/4885RECQL 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.